Member Info for luvelyjubley

I would like to think that when Mr Parker said "Very Soon" (ABOUT 3 MONTHS AGO) the results of the initial trial of 1801 would be peer reviewed and published in a journal that this should be the next RNS.

This publication together with indications of what biomarker indications look promising, a summary of the results of the AI study, any update on the positive aspects of the crossing of the blood brain barrier and confirmation of the start of the tox study and this would definitely "let the world know what we have"

The other news expected was 737 and 1802 was to be packaged up and advertised on the US Market looking for a strategic partner to take them forward. With the FDA approving another chk inhibitor in combination recently then with the substantial track record of trials with 737 in combination with other drugs must make it a viable candidate for a large pharma looking for a chk inhibitor to work with their own drug or trial it with 1802.

It has been a while since we had this number of share transactions with SAR so something must be stiring?

Another great article on the potential of tyk2 drug, its only a pity that there are no similar articles about ours.

It's 12 months since we completed the initial trial and over 3 months when our Chairman said we would have a peer review and publication "VERY SOON"

Come on Mr Parker give us some action and build on the confidence shown yesterday,

Get some of the directors to buy some shares

Publish the document ( on the Internet) "so the world can see what we have" instead of hiding it in the bottom drawer

Give us an update on the AI trial

Get ALL of our products marketed on the American stage Trumps policies favour development on home soil.

Still time for a little rally before end of year and build some confidence before the start of the Tox study in the new year.

Now that the FCA have approved a combination of a chk drug and another for specific treatment and we know 737 has been trialed in various combos over the last few years, I wonder how many major pharmas are looking at their own drugs and eyeing up a chk of their own to run with.

The news must have raised the profile of 737 somewhat and I just hope the recent trial of 737 with the Chinese company has stirred an interest, if they run with it they will not hang about and I would imagine it would be fast tracked in unmet medical needs first.

So much potential 737 progress, 1801 initial trial results due for publication (very soon) 1801 tox results ( an update of the positives from the trial which must have been good enough to now focus on an efficacy trial) the outcome of the AI analysis, the results of the bio markers and crossing the blood brain barrier.

If the BOD are not capable of getting at least one major pharma on board with all that we have then they need to have a good look at themselves, have a clear out and bring fresh resources onboard.

Hi wobble thanks for posting the article, looks like they have set aside finance for our claim.

It makes you wonder if after it has run its course with all of the claims and arbitration are complete, what happens to the oil and gas that's in the ground? The value has increased substantially over the years.

Is it a case of the government fighting to the bitter end knowing what ever they have to pay out will still be less than the asset and they will get it back and develop it anyhow.

Some nice deals still going through as some large pharmas doing their Christmas shopping, with the current trend in USA tarrifs a lot of companies eill be looking to buy and develop their portfolios inside the USA.

Come on Mr Parker get the paperwork signed off for our deal.

Any company invested or thinking of investing in the European market will be watching the outcome of cases such as this.

If the outcome is seen as being fair then it will inspire confidence in the legal support and send a shot across the bows of government departments and individuals with their own agendas.

Hi krone

Nice to see a comparison with a similar drug that is further ahead and that we look to be more advantageous, if any large pharma wants a tyk2 to add to their portfolio we must be on their radar.

It would be nice to think that the BOD have been working with a strategic partner and they are working through the present scenario together so as to decide what next.

Hopefully the AI results should be due "very soon" and available before the AGM.

Come on Mr Parker give us a decent RNS about a commercial deal.

Hi Aber I am also thinking they have something positive to announce before agm, I can not see them wanting to go in front of a lynch mob.

With 737 and flt3 being trialed by chineese researchers they may be interested to onlicense, they would not hang about if they sensed the chance of success and are hungry for competition against USA drug companies. A nice deal now would be perfect timing.

The endpoints publication today mentioned a number of Mergers and Aquisitions and a statement from Merc said they were on the lookout to strengthen their portfolio with more and from a range of sizes to cover their future pipeline and to get development in the USA . If they have been keeping an eye on SAR then it's an opportune moment to snap up 1801, 1802 and 1803 for a bargain, the initial trial results plus the output from the AI modelling may be enough to have a crack at SAR.

The BOD need a strategic partner to move forward with because at present the lack of shareholder confidence the BOD will be out on a limb if a low ball offer comes in.

Here's hoping for some decent news to give us some confidence.

Potnak if they have been working with a strategic partner they could show their hand and support the company to give stability and confidence that we are not just bouncing along on our own.

If the BOD can not gain the confidence of the shareholders with positive action and a low ball offer comes in the shareholders may disregard any advice from the BOD and take the offer to get out and see the back of them.

Anything north of £1 will do me nicely.

I have noticed lately that a few negative threads are just being repeated by seasoned holders, anyone who is being paid to stir up negative sentiment will be clapping their hands.

Instead of venting on here why don't we all start messaging the company to give them a prod?

With tyk2 being proven to be successful by a few other companies and the recent announcement of crossing the blood brain barrier, any large pharma that is interested in developing their own product will be on the lookout for a little pharma to snap up at a bargain price.

The present set back with our tox trial makes Sareum even more vulnerable for a takeover, if the initial trial data (which was going to be released VERY SOON and has been held back for some reason) and the initial results of the tox study ( such as max dose reached with no adverse effects) were looking good before they went pear shaped then any strategic partner that was involved with Sareum might just decide they have enough confidence to make an offer and take it from here.

The attitude of Mr Parker in brushing aside the question of a need for a CEO could be as they have the future mapped out.

I believe GSK have a new CEO who will be looking to make their mark to take them forward in the next 5 to 10 years, what better way than buy a small pharma like SAR with a range of drugs and run a number of trials in parallel get 737 moving, 1801, 1802 and 1803, get a team looking at the issues with FLT and keep our BOD member on a retainer to run through the SKILL software to see if there are any further opportunities to be HD.

Fortune favours the brave and with the present sentiment it would not take much to get a deal over the line.

There are many deals that have been done on phase 1 data alone,

Hi krone another nice article about a similar drug to ours that is progressing, its a pity that Mr Parker did not get the initial trial data with the results of the biomarkers published when he said "very soon" and we might have pipped this company to the post as being the first to cross the blood brain barrier.

The silence is deafening and we can only hope that they are working their socks off to get the show back on track with substantial news of a strategic partner to pick up the running with the progression of the likes of 1802 while we sort out the tox study of 1801.

I believe it has been mentioned that 1802 could be used in patients with an unmet medical need and a tox study done in parallel.

Come on Mr Parker lead from the front and give us something to cheer about hopefully "very soon".

Mm's keeping a 14% spread they must have a sense something going to move.

As a few people have had a dabble with AI looking at different scenarios I asked to list any pharma companies that have been bought out after a phase 1 trial in the last 5 years and by which company.

There were 5 and surprising all the buyers were the big boys with the cash, one of them was a tyk2 in 23.

As most were for single drugs if anyone is watching Sareum they stand to get a few for their money so anything can happen.

To avoid a low ball offer being accepted by the shareholders then the BOD need to give us some confidence and buy some shares to stabilise the shareprice. They could also publish the initial report which over 12 weeks ago would be "very soon"

Hi krone I belive the same has been said about 737 where a partner is interested in progressing.

I was expecting one pharma taking the lot and buying sar outright (which could still happen anytime especially now when the share price being so low as well as shareholder confidence being trashed) a low ball offer just might get accepted.

On the other hand if the BOD could get one drug into a partnership followed by a second then the tox study complete ( then another partnership) then the results of the AI and further development of 1803, the company could have enough revenue to pay dividends (to keep a good shareholder / institution portfolio) and have enough for further research and development of 1804, 1805.

Until the BOD can get the first deals sorted we are going to bounce along, it's all to play for and will only take "ONE" partnership to kick it all off so come on Mr Parker "VERY SOON" get cracking give us a nice Xmas pressie.

The news yesterday about the USA tarrifs on drug companies is already staring up the market, it mentioned 4 pharmas who are building facilities who have broken ground on the construction. These us companies are going to want to own and manufacture the drugs in the USA so will be scouring the market for little fish to swallow.

With the patents expiring on a few drugs in the next few years Sareum must be a potential target, 737, 1802 and I wonder how many were surprised when they announced 1803 crossing the blood brain barrier.

I personally feel the investor Q&A yesterday was to buy the BOD some time to get things lined up before AGM

If the BOD wanted to inspire some confidence they could buy some shares, they could also release the results of the initial trial ( very soon) come on Mr Parker get them published on the Internet so the world we can see what we have.

The new 1803 could be patented up before the AI results are announced, 1802 started in trials of unmet medical needs still plenty to do.

What about us? Instead of putting loads of stuff up on this BB why not get organised? I belive Thoth started to set up a shareholder group where everyone contacted him and gave them their details, is there any appetite to do something similar? Could set up a private Facebook page and take it from there.

Next

If they have been working closely with a strategic partner since late last year and have been under an NDA as has been mentioned a few times then I would image they would have been following the trial on a daily basis and involved in the decisions.

It would depend how they wanted this to progress if they are pulling the strings, if they have had a good working relationship with our BOD and supportive of the work going on with 1803 they may show their hand and announce a partnership as part of the rns which will set us well on our way, fingers crossed.

Hi ponak regarding which way the BOD went re the trial or tox study, just wondering who's decision was it?

All the vibes suggest that someone (hopefully a large pharma) has been guiding the BOD in the direction they see the best position to make an offer to take over the company and run with it after then.

Mr Parkers comment at last years AGM (something on the lines that it might be the last AGM, implies a takeover not an onlicense) the long delay and radio silence after the initial trial (someone doing due diligence on the results of trial and bio markers), the decision to bring control of 737 into Sareum ( part of the package so buyer has a few strings to their bow and this already proven in multiple combo trials)

Then the AI partnership to broaden the portfolio of options for 1801 whilst the tox study ongoing.

It would be one hell of a Xmas present if the initial results of the early stage of the tox study (max dose established etc, no initial adverse effects ) was enough for a large pharma to step in and make an offer, we could even give them a bit discount for the Xmas sales.

Here's hoping for some fantastic news next week.

I would like to think that when we went into the initial trial we had a strategic partner on board who was shadowing the initial trial and the results of the bio markers, the radio silence for the months after the trial and the change of direction from a further trial into a tox study again hopefully at the request of the strategic partner.

The results of the bio markers seemed to stir the BOD regarding crossing the blood brain barrier and initiating a partnering with an AI company for further analysis.

I would like to think the strategic partner has also been heavily involved in the tox study so is fully aware of what has gone on and will be guiding our BOD through the present situation.

If we do have a large pharma on board it would be rather decent of them to show their support and either make an offer to pick up the pieces from here and drive the next stage by taking 1801 off our hands for a deal or put an offer on the table to take the whole company.

Come on Mr Parker give them a nudge.

I wish I was dishing out the wages at Sareum and when they ask when they were getting paid the reply would be "very soon" but you said that last month and its now more than 2 months since we have had anything. Don't worry it will get sorted "very soon"

While time trundles along the Patent clocks are ticking and no obvious progress to report.

I think that it is high time the shareholders actually have a say in what is going on in this company and play an active part in its guidance.

A vote of no confidence in the chairman and the exec directors at the AGM should stir them up, we need shareholder representation on the BOD, a clear mandate from the shareholders as to what they expect to happen to 737 1801 etc

If the BOD are not capable of taking forward the existing products into comercial deals then we need a clear out and get directors who can move progress.